Kiilerichyildiz8960

Lymph node dissection in gastric cancer had been controversial, but recent data have led us to the conclusion that D-2 dissection should be the standard of care for potentially curable advanced gastric carcinoma. In this study, we present our single-institution experience of D-2 lymph node dissection.

From January 2013 to September 2018, 115 patients of gastric cancer were treated with D-2 gastrectomy, 91 of whom met the criteria for study analysis. Data were statistically described as frequencies and percentages where appropriate. Survival curves were plotted using the Kaplan-Meier method, and Cox regression was used to assess the risk among groups. A

value <0.05 was considered to be statistically significant at 95% confidence interval.

The majority of patients (86.8%) had Clavien-Dindo grade I postoperative surgical complications; 90-day mortality was seen in five (5.5%) patients. Patients with stages I, II, and III had survival rates of 100%, 71.4%; 53.2%, 44.4%; and 27.8%, 28.1%, respectively, overall 5-year survival.

(

) is a major Crohn's disease (CD) susceptibility gene, especially in the East Asian population, and is also known to be associated with some clinical phenotypes, such as stricturing and penetrating behavior. This study aims to investigate the association between

genotype and the long-term therapeutic outcomes of infliximab and adalimumab in Japanese CD patients.

We investigated 119 biologic-naïve CD patients treated with infliximab or adalimumab.

-358C/T (rs6478109) was genotyped as a tag single nucleotide polymorphism (SNP) for CD risk or nonrisk haplotype of

(the -358C allele is a risk allele for CD development). We compared the long-term therapeutic outcomes of anti-tumor necrosis factor (TNF) antibodies between the

-358C/C group and the C/T+T/T group.

Sixty-nine cases (58.0%) were homozygous for the risk allele (

-358C/C group), and 50 cases (42.0%) were heterozygous for the risk allele or homozygous for the protective allele (

-358C/T+T/T group). No significant differences were found in the cumulative retention rates and the relapse-free survival between the

genotypes. However, the surgery-free survival was significantly lower in the

-358C/C group than in the C/T+T/T group (log-rank test,

 < 0.05). https://www.selleckchem.com/ Multivariate analysis showed that

-358C/C was identified as an independent risk factor for surgery (hazard ratio, 4.67; 95% confidence interval, 1.39-22.1;

= 0.025).

An association was found between the

genotype and the therapeutic outcomes of anti-TNF therapy. Our data indicate that the design of customized therapy with anti-TNF antibodies using

genomic information could be effective in the future.

An association was found between the TL1A genotype and the therapeutic outcomes of anti-TNF therapy. Our data indicate that the design of customized therapy with anti-TNF antibodies using TL1A genomic information could be effective in the future.

Coronavirus disease 19 (COVID-19) has caused over 200 000 deaths worldwide. Thailand announced the first confirmed case outside mainland China in January 2020. The disease also spread widely across Association of Southeast Asian Nations (ASEAN). Gastrointestinal manifestations could be presenting symptoms of COVID-19. This study aimed to determine the prevalence of gastrointestinal manifestations of COVID-19 patients in Thailand and review important aspects of this disease in ASEAN.

Thai patients diagnosed with COVID-19 at Thammasat University Hospital, Thailand, were evaluated between 1 January 2020 and 30 April 2020. Patients' data, clinical presentation, exposure risk, past medical history, laboratory results, and treatment outcomes were extensively reviewed.

A total of 352 COVID-19 tests were performed, and 40 patients with positive tests were studied. The mean age was 30.5 years, and 55% were female. Most (82.5%) had no underlying diseases. Comorbidities were associated with severe COVID-19 (odds rcourse. Patients presenting with only gastrointestinal symptoms should raise clinical suspicion for COVID-19 in areas with high disease incidence. Clinically severe COVID-19 was associated with comorbidities and diarrhea.

Severe acute pancreatitis (SAP) is commonly associated with intra-abdominal hypertension (IAH). This acute increase of intra-abdominal pressure (IAP) may be attributed to early organ dysfunction, leading to an increased morbidity and mortality. To assess the incidence of raised IAH and its correlation with other prognostic indicators and various outcomes in SAP.

This was a prospective observational study in patients of SAP between July 2009 and December 2010. All patients of SAP who were admitted to the hospital within 2 weeks of onset of pain were included in the study. A total of 35 patients with SAP were included in the study. Among these, 25 (71.4%) were males. All our patients had raised IAP; however, IAH was present in 51.4% (18/35). Patients with IAH were found to have a higher APACHE II score (88.9

5.9%;

 < 0.001), infectious complications (72.2

5.9%;

 < 0.001), circulatory failure (88.9

0%;

 < 0.001), and respiratory failure (100

41.2%;

 < 0.001). All the eight (22.8%) patients who succumbed to sepsis had IAH. Patients with IAH were found to have a significantly longer intensive care unit (ICU) stay (17.72

12.29 days) and in-hospital stay (24.89

12.29 days).

IAH is a good negative prognostic marker in SAP, seen in up to 51.4%. IAH was found to have a significant negative impact on the outcome in terms of increased mortality, morbidity, in-hospital stay, and ICU stay among the patients of SAP.

IAH is a good negative prognostic marker in SAP, seen in up to 51.4%. IAH was found to have a significant negative impact on the outcome in terms of increased mortality, morbidity, in-hospital stay, and ICU stay among the patients of SAP.

Prebiotics are nondigestible oligosaccharides that are metabolized by colonic bacteria, resulting in a change in the pH of the colonic milieu as well as modifying the microbiome of the colon. The purpose of this retrospective study was to determine whether concomitant lactulose administration affected the

infection rate among hospitalized adult patients receiving antibiotics.

We retrospectively reviewed inpatient medical records of patients in a large teaching hospital admitted during a one-year period. Individuals treated with antibiotic therapy during the course of their hospitalization were considered for inclusion in the study. Patients were evaluated for development of

infection, as well as concomitant lactulose therapy for hepatic encephalopathy. The incidence of

infection among patients who received lactulose and antibiotic therapy was compared with that among those who received antibiotic therapy alone.

Patients who received lactulose and antibiotic therapy were slightly older (

= 87, mean age 67) than patients who received antibiotic therapy alone (

= 103, mean age 60).